Description of Relugolix Use in Patients With Prostate Cancer Within the VHA
Status
Conditions
Treatments
Study type
Funder types
Identifiers
Details and patient eligibility
About
The purpose of this real-world study is the learn about the demographics and clinical characteristics of patients with prostate cancer who initiated relugolix
Full description
Prostate cancer (PC) is the most common cancer and the second leading cause of cancer death among men in the United States. Androgen deprivation therapy (ADT) such as injectable luteinizing hormone-releasing hormone (LHRH) agonists (e.g., leuprolide) is the standard of care for PC patients. ADT treatment can suppress testosterone level to castrate level and delay the progression of the disease.
Relugolix is a recently approved oral GnRH antagonist. While the introduction of relugolix has offered a unique opportunity for patients with PC, it's vital to understand how it is being used in real-world.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
- Male with ≥ 1 diagnosis for PC
- Had ≥ 2 prescriptions of relugolix on or after the first observed PC diagnosis.
- Index date: the initiation date of relugolix
- At least 18 years old at the index date
Exclusion criteria
- had surgical castration (bilateral orchiectomy) any time before the index date
Trial design
507 participants in 1 patient group
Trial contacts and locations
Loading...
Central trial contact
Pfizer CT.gov Call Center
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal